
Investors
OMX Stockholm

Annual Report 2022
Sustainability Report 2022
Pioneering innovative lifesaving treatments
Hansa Biopharma in brief
We are leveraging our proprietary antibody-cleaving enzyme technology platform to target pathogenic or disease causing antibodies. Our first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate IgG antibodies in the plasma and tissue through a single intravenous treatment. We are currently investigating the use of this molecule for treating and preventing rare conditions caused by IgG antibodies in the acute phase, within transplantation, autoimmunity, gene therapy and oncology.
From imlifidase, we have developed a first-in-class therapy to enable kidney transplantation in highly sensitized patients. The European Commission has conditionally authorized our first product for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.
Our research and development program is also advancing the Company’s enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.
Hansa Biopharma is based in Lund, Sweden and with operations in other European countries and in the U.S.
Hansa Biopharma's fact sheet
Our Equity story
Targeting rare diseases with a high unmet medical needs
Commercializing the first authorized product in first markets and indications
Evolving into a fully integrated biopharmaceutical company
Leveraging our proprietary antibody cleaving enzyme technology

Upcoming events
Annual General Meeting 2023
Half-year Report for January-June 2023
Erik Penser Company Day, Stockholm
Press releases
Our latest press releases
01/06/2023
30/05/2023
Regulatory press release
29/05/2023
27/04/2023
Upcoming
Milestones and near-term news flow
2023 |
|
---|---|
2024 |
|

Sign up to receive updates on the latest company news and filings
Klaus Sindahl
Head of Investor Relations
Mobile: +46 (0) 709 298 269